PDMR Shareholding / SIP & Total Voting Rights
Diaceutics announced that trustees purchased Shares on behalf of three PDMRs on 29 October 2026 — 71, 74 and 74 shares at 203.8p each — under the SIP with the Company matching purchases 1:1 and continuing monthly until further notice; 3,896 matched Shares were issued to the UK Trust on 3 November 2026 and 53,810 Shares were allotted during the period, bringing total shares in issue to 85,291,958, while a block listing of 1,500,000 Shares remains in place to facilitate option exercises.
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
New York, Belfast and London, 4 November 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has been notified that on 29 October 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 3,896 Shares on 3 November 2026 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.
During the period from the last Total Voting Rights Announcement on 6 October 2026, 53,810 Shares were allotted to settle certain employee share option exercises during September 2026 in addition to the Shares allotted as a result of the Share Incentive Plan transactions announced today. As a result, the number of Shares Diaceutics has in issue is 85,291,958. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
| a. | Name | Susanne Munksted |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Growth Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 203.8 p | 71 | |
| Conditional share award: | ||
| Price(s) | Volume(s) | |
| Nil | 71 | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Jordan Clark |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Customer Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 203.8 p | 74 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 74 | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Nick Roberts |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Finance Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 203.8 p | 74 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 74 | |
| f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.